These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35757784)

  • 1. Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab.
    Liu J; Chang HW; Grewal R; Cummins DD; Bui A; Beck KM; Sekhon S; Yan D; Huang ZM; Schmidt TH; Yang EJ; Sanchez IM; Nakamura M; Bhattarai S; Thibodeaux Q; Ahn R; Pauli M; Bhutani T; Rosenblum MD; Liao W
    JID Innov; 2022 May; 2(3):100094. PubMed ID: 35757784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
    Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
    J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab.
    Mehta H; Mashiko S; Angsana J; Rubio M; Hsieh YM; Maari C; Reich K; Blauvelt A; Bissonnette R; Muñoz-Elías EJ; Sarfati M
    J Invest Dermatol; 2021 Jul; 141(7):1707-1718.e9. PubMed ID: 33524368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
    Boudreaux BW; Pincelli TP; Bhullar PK; Patel MH; Brumfiel CM; Li X; Heckman MG; Pittelkow MR; Mangold AR; Sluzevich JC
    Br J Dermatol; 2022 Nov; 187(5):650-658. PubMed ID: 35701384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep resolution of clinical, cellular, and transcriptomic inflammatory markers during 52 weeks of IL-17A inhibition by secukinumab.
    Tomalin LE; Kolbinger F; Suprun M; Wharton KA; Hartmann N; Peters T; Glueck A; Milutinovic M; Krueger JG; Suárez-Fariñas M
    Clin Exp Dermatol; 2024 Jan; ():. PubMed ID: 38240024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8
    Liu J; Chang HW; Huang ZM; Nakamura M; Sekhon S; Ahn R; Munoz-Sandoval P; Bhattarai S; Beck KM; Sanchez IM; Yang E; Pauli M; Arron ST; Fung-Leung WP; Munoz E; Liu X; Bhutani T; North J; Fourie AM; Rosenblum MD; Liao W
    J Allergy Clin Immunol; 2021 Jun; 147(6):2370-2380. PubMed ID: 33309739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of Adaptive Immune Cell and NK Cell Subsets in Patients With Ankylosing Spondylitis After IL-17A Inhibition by Secukinumab.
    Jiang Y; Yang M; Zhang Y; Huang Y; Wu J; Xie Y; Wei Q; Liao Z; Gu J
    Front Pharmacol; 2021; 12():738316. PubMed ID: 34721027
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
    Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis.
    Liu Y; Zhang C; Li B; Yu C; Bai X; Xiao C; Wang L; Dang E; Yang L; Wang G
    J Dermatol Sci; 2021 Feb; 101(2):84-92. PubMed ID: 33334656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.
    Blair HA
    Paediatr Drugs; 2021 Nov; 23(6):601-608. PubMed ID: 34665445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.
    Bhat RM; Leelavathy B; Aradhya SS; Gopal MG; Pratap DV; Mubashir M; Srinivas P; Pande SY; Thavkar AS
    Indian Dermatol Online J; 2017; 8(1):16-24. PubMed ID: 28217466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients.
    Hu Y; Chen Y; Chen Z; Zhang X; Guo C; Yu Z; Xu P; Sun L; Zhou X; Gong Y; Yu Q; Shi Y
    Front Cell Dev Biol; 2021; 9():799560. PubMed ID: 35186952
    [No Abstract]   [Full Text] [Related]  

  • 16. Tissue-Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis.
    Leijten EF; van Kempen TS; Olde Nordkamp MA; Pouw JN; Kleinrensink NJ; Vincken NL; Mertens J; Balak DMW; Verhagen FH; Hartgring SA; Lubberts E; Tekstra J; Pandit A; Radstake TR; Boes M
    Arthritis Rheumatol; 2021 Jul; 73(7):1220-1232. PubMed ID: 33452865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
    Frieder J; Kivelevitch D; Menter A
    Ther Adv Chronic Dis; 2018 Jan; 9(1):5-21. PubMed ID: 29344327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation.
    Bovenschen HJ; Seyger MM; Van de Kerkhof PC
    Br J Dermatol; 2005 Jul; 153(1):72-8. PubMed ID: 16029329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IκBζ is a key player in the antipsoriatic effects of secukinumab.
    Bertelsen T; Ljungberg C; Litman T; Huppertz C; Hennze R; Rønholt K; Iversen L; Johansen C
    J Allergy Clin Immunol; 2020 Jan; 145(1):379-390. PubMed ID: 31622687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.